Mabwell (Shanghai) Bioscience Co., Ltd. (HKG:2493)

Market Cap	18.33B +119.4%
Revenue (ttm)	847.19M +321.1%
Net Income	-1.05B
EPS	-2.62
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,094,000
Average Volume	3,401,119
Open	26.64
Previous Close	26.64
Day's Range	26.00 - 27.00
52-Week Range	25.48 - 31.46
Beta	n/a
RSI	n/a
Earnings Date	May 13, 2026

About HKG:2493

Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injection; and JUNMAIKANG, an autoimmune Adalimumab injection. It also provide...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Employees: 1,325
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2493

Financial Performance

In 2025, HKG:2493's revenue was 662.52 million, an increase of 231.62% compared to the previous year's 199.78 million. Losses were -969.33 million, -7.14% less than in 2024.

Financial numbers in CNY